Compare YSXT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | VRCA |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 32.7M |
| IPO Year | 2024 | 2018 |
| Metric | YSXT | VRCA |
|---|---|---|
| Price | $1.55 | $8.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 866.0K | 402.7K |
| Earning Date | 07-31-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.30 | ★ N/A |
| Revenue Growth | 22.04 | ★ 234.73 |
| 52 Week Low | $1.25 | $3.28 |
| 52 Week High | $9.96 | $9.82 |
| Indicator | YSXT | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 30.97 | 62.44 |
| Support Level | $1.25 | $7.82 |
| Resistance Level | $2.45 | $9.78 |
| Average True Range (ATR) | 0.32 | 1.18 |
| MACD | -0.08 | 0.10 |
| Stochastic Oscillator | 20.83 | 64.93 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.